Global Post-traumatic Stress Disorder (PSTD) Therapeutics Market 2020-2024 | Evolving Opportunities with AstraZeneca Plc and Azevan Pharmaceuticals Inc. | Technavio
March 9, 2020LONDON–(BUSINESS WIRE)–#GlobalPosttraumaticStressDisorderTherapeuticsMarket–The global post-traumatic stress disorder (PSTD) therapeutics market is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of about 9% during the forecast period. Request free sample pages
Read the 120-page report with TOC on “Post-traumatic Stress Disorder (PSTD) Therapeutics Market Analysis Report by Product (Antidepressants, Anxiolytics, and Other PTSD therapeutics), Geographic Segmentation (APAC, Europe, MEA, North America, and South America), and the Segment Forecasts, 2020-2024”.
The market is driven by the rising prevalence of PTSD. In addition, the increasing initiatives by public and private organizations are anticipated to boost the growth of the PSTD therapeutics market.
According to studies, 6-8 out of 10 victims of severe traumatic events experience PTSD. Research shows that over 7.5 million Americans are treated for PTSD annually. PTSD victims have become one of the leading causes of suicide cases in the US. Around 800,000 to 1,000,000 Australians suffer from PTSD at any given time. The military population has witnessed a higher prevalence rate of PTSD in comparison to civilians. All these factors are contributing to the increasing demand for PSTD therapeutics for treatment of people diagnosed with PTSD. Thus, the rising prevalence of PTSD is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Post-Traumatic Stress Disorder (PSTD) Therapeutics Market Companies:
AstraZeneca Plc
AstraZeneca Plc operates the business under the Biopharmaceuticals segment, through which the company focuses on the discovery and development of new products. The company offers Quetiapine for the treatment of PTSD.
Azevan Pharmaceuticals Inc.
Azevan Pharmaceuticals Inc. operates through the Products business unit. The company is engaged in drug development for novel therapeutics. The company offers SRX246, which is currently under the Phase II trial.
Bionomics Ltd.
Bionomics Ltd. operates under two business segments, namely Drug discovery and development, and Contract services. The company offers BNC210 for the treatment of post-traumatic stress disorder and other trauma and stressor related disorders.
Eli Lilly and Co.
Eli Lilly and Co. offers products through the following business segments: Human pharmaceutical products and Animal health products. The company offers Prozac (fluoxetine) for the treatment of PTSD patients.
GlaxoSmithKline Plc
GlaxoSmithKline Plc offers products through the following business segments: Pharmaceuticals, Consumer healthcare, and Vaccines. The company offers Paxil, which is used for the treatment of major depressive disorders (MDD) such as social anxiety disorder, panic disorder, PSTD, and obsessive-compulsive disorder.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Post-traumatic Stress Disorder (PSTD) Therapeutics Market Product Outlook (Revenue, USD Million, 2020-2024)
- Antidepressants
- Anxiolytics
- Other PTSD therapeutics
Post-traumatic Stress Disorder (PSTD) Therapeutics Market Geographic Outlook (Revenue, USD Million, 2020-2024)
- APAC
- Europe
- MEA
- North America
- South America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care Include:
Neurologic Disorders Therapeutics Market – Global Neurologic Disorders Therapeutics Market by application (CNS and PNS) and geography (Asia, Europe, North America, and ROW).
Orthostatic Hypotension Drugs Market – Global Orthostatic Hypotension Drugs Market by product (midodrine, Northera (droxidopa), fludrocortisone, and other drugs) and geography (Asia, Europe, North America, and ROW).
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: https://www.technavio.com